Physician profile
Mohit Bhasin
NPI 1124070693
$3,150.74
in general payments reported to CMS, 2019-2025
24 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $189 · 2021: $1,806 · 2022: $44.27 · 2023: $137 · 2024: $126 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,343.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $218.47 | 2019-2022 | |
| Amgen INC. | $140.66 | 2019-2021 | |
| Amarin Pharma, INC. | $136.54 | 2021 | |
| Neosoft, LLC | $129.73 | 2025 | |
| W. L. Gore & Associates, INC. | $122.72 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Siemens Medical Solutions USA, INC. | $122.21 | 2024-2025 | Naeotom Alpha, Somatom Pro.Pulse |
| Janssen Pharmaceuticals, INC | $119.94 | 2019-2023 | Xarelto |
| Irhythm Technologies, INC. | $116.67 | 2019 | |
| Beta Bionics, INC. | $98.41 | 2024 | Ilet Bionic Pancreas |
| Philips North America LLC | $83.12 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.69 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.16 | 2019-2021 | |
| Astellas Pharma US INC | $60.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2019-2021 | |
| Pfizer INC. | $37.19 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $33.74 | 2021 | |
| Merck Sharp & Dohme LLC | $30.22 | 2021 | |
| Bardy Diagnostics, INC. | $29.91 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.88 | 2019 | |
| Biotronik INC. | $23.09 | 2021 | |
| Medtronic, INC. | $21.21 | 2021 | |
| Metuchen Pharmaceuticals | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.